Alzheimer’s drug fails at Phase 3

Friday 5 March 2010

An investigational drug for patients with Alzheimer’s disease, Dimebon (latrepirdine), has failed in a Phase 3 trial because it could not show statistically significant improvements in patients compared with placebo for cognition and global function.

Full text available to subscribers only. Click here for information on subscribing to MedNous.